These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Myelin-specific CD8 T cells in the pathogenesis of experimental allergic encephalitis and multiple sclerosis. Steinman L J Exp Med; 2001 Sep; 194(5):F27-30. PubMed ID: 11535639 [No Abstract] [Full Text] [Related]
7. Heat shock proteins and the immunopathogenesis of multiple sclerosis. Linington C Neuropathol Appl Neurobiol; 1995 Dec; 21(6):483-6. PubMed ID: 8745235 [No Abstract] [Full Text] [Related]
8. The potential role of T cell migration and chemotaxis as targets of glucocorticoids in multiple sclerosis and experimental autoimmune encephalomyelitis. Fischer HJ; Schweingruber N; Lühder F; Reichardt HM Mol Cell Endocrinol; 2013 Nov; 380(1-2):99-107. PubMed ID: 23578583 [TBL] [Abstract][Full Text] [Related]
9. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. Brunmark C; Runström A; Ohlsson L; Sparre B; Brodin T; Aström M; Hedlund G J Neuroimmunol; 2002 Sep; 130(1-2):163-72. PubMed ID: 12225898 [TBL] [Abstract][Full Text] [Related]
10. Immunoglobulins treatment in multiple sclerosis and experimental autoimmune encephalomyelitis. Achiron A; Miron S Mult Scler; 2000 Oct; 6 Suppl 2():S6-8; discussion S33. PubMed ID: 11188777 [TBL] [Abstract][Full Text] [Related]
11. Neuroimmunology of multiple sclerosis and experimental allergic encephalomyelitis. Stuerzebecher S; Martin R Neuroimaging Clin N Am; 2000 Nov; 10(4):649-68 ,vii-viii. PubMed ID: 11359717 [TBL] [Abstract][Full Text] [Related]
12. Immunomodulatory effects of the ether phospholipid edelfosine in experimental autoimmune encephalomyelitis. Abramowski P; Steinbach K; Zander AR; Martin R J Neuroimmunol; 2014 Sep; 274(1-2):111-24. PubMed ID: 25086877 [TBL] [Abstract][Full Text] [Related]
13. Animal models: Not close enough. Rice J Nature; 2012 Apr; 484(7393):S9. PubMed ID: 22509510 [No Abstract] [Full Text] [Related]
14. Cytokines in the pathogenesis and therapy of autoimmune encephalomyelitis and multiple sclerosis. Willenborg DO; Staykova MA Adv Exp Med Biol; 2003; 520():96-119. PubMed ID: 12613575 [No Abstract] [Full Text] [Related]
16. Copolymer 1 from the laboratory to FDA. Teitelbaum D; Sela M; Arnon R Isr J Med Sci; 1997 Apr; 33(4):280-4. PubMed ID: 9347880 [No Abstract] [Full Text] [Related]
17. Dynamics of the autoimmune T-cell repertoire in experimental allergic encephalomyelitis and in multiple sclerosis. Salvetti M; Ristori G; Buttinelli C; Pozzilli C Immunol Today; 1994 Feb; 15(2):89-90. PubMed ID: 8155268 [No Abstract] [Full Text] [Related]
18. New concepts in the immunopathogenesis of multiple sclerosis. Hemmer B; Archelos JJ; Hartung HP Nat Rev Neurosci; 2002 Apr; 3(4):291-301. PubMed ID: 11967559 [No Abstract] [Full Text] [Related]
19. Glatiramer acetate for the treatment of multiple sclerosis: evidence for a dual anti-inflammatory and neuroprotective role. Liblau R J Neurol Sci; 2009 Dec; 287 Suppl 1():S17-23. PubMed ID: 20106343 [TBL] [Abstract][Full Text] [Related]
20. Evaluating the evidence for multiple sclerosis as an autoimmune disease. Altmann D Arch Neurol; 2005 Apr; 62(4):688; author reply 688-9. PubMed ID: 15824275 [No Abstract] [Full Text] [Related] [Next] [New Search]